This is why we are pioneering the development of selective translation regulator inhibitors (STRIs): a new class of cancer therapies designed to overcome cancer’s complexity.
STRIs simultaneously block production of multiple disease-driving proteins as a single drug. This is possible through targeting a central node (eIF4F) where two major cancer signaling pathways converge and activate a burst of protein synthesis that drives multiple disease processes.
In cancer, processes that are normally tightly controlled become dysregulated, including translation. This leads to the aberrantly high production of multiple proteins that cause uncontrolled growth, immune evasion and metastasis. We believe that our STRIs can inhibit the production of key disease-driving proteins, which tumors have hijacked for their benefit, all while preserving the cell’s normal, healthy state. Our STRIs, which can be synergistic with existing therapies and those in development, are specifically designed to block production of oncoproteins, immune suppression factors and resistance mechanisms that cancer uses to evade therapeutic intervention.
eFFECTOR was founded on pioneering research in the laboratories of Drs. Davide Ruggero and Kevan Shokat and subsequently licensed proprietary applications of translational profiling technology from the University of California, San Francisco. Our scientific founders and management team comprise industry veterans who have played important roles in the discovery and development of marketed small molecule drugs, monoclonal antibody therapeutics and cellular immunotherapies in oncology and other disease areas.
